{
  "id": "6020ad161cb411341a000082",
  "type": "yesno",
  "question": "Is liraglutide effective for weight reduction?",
  "ideal_answer": "Yes, liraglutide is effective and approved for weight reduction.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19930006",
    "http://www.ncbi.nlm.nih.gov/pubmed/31770497",
    "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
    "http://www.ncbi.nlm.nih.gov/pubmed/17039422",
    "http://www.ncbi.nlm.nih.gov/pubmed/27073422",
    "http://www.ncbi.nlm.nih.gov/pubmed/27600499",
    "http://www.ncbi.nlm.nih.gov/pubmed/32506681",
    "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
    "http://www.ncbi.nlm.nih.gov/pubmed/27995594",
    "http://www.ncbi.nlm.nih.gov/pubmed/32410565",
    "http://www.ncbi.nlm.nih.gov/pubmed/26284720",
    "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
    "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
    "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
    "http://www.ncbi.nlm.nih.gov/pubmed/31203802",
    "http://www.ncbi.nlm.nih.gov/pubmed/32202085"
  ],
  "snippets": [
    {
      "text": "Liraglutide has been approved at higher dose for obesity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30678612",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This meta-analysis finds a significant reduction in body weight with orlistat (N = 10,435; \u2206 -3.07 Kg, 95% CI, -3.76 to -2.37), phentermine plus topiramate (N = 2985; \u2206 -9.77 Kg; 95% CI, -11.73 to -7.81), lorcaserin (N = 16,856; \u2206 -3.08 Kg; 95% CI, -3.49 to -2.66), naltrexone plus bupropion (N = 3239; \u2206 -4.39 Kg; 95% CI, -5.05 to -3.72) and liraglutide (N = 4978; \u2206 -5.25 Kg; 95% CI, -6.17 to -4.32), compared to placebo (all p < 0.00001).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31770497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: In patients with T1D, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31203802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (-6.8%) liraglutide (-5.4%), naltrexone/bupropion (-4.0%), lorcaserin (-3.1%), and orlistat (-2.9%). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32202085",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: Currently, the FDA has approved several molecules for the treatment of obesity, both in monotherapy and in combination. Pharmacological monotherapies focus mainly on a single protein target and include orlistat, lorcaserin and liraglutide while the combination molecules propose a multitarget approach and include phentermine/topiramate and naltrexone/bupropion. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32410565",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phentermine-topiramate and liraglutide have been associated with the highest probability of at least 5% weight loss. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32410565",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, high-dose liraglutide has been used for weight control in non-diabetic patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506681",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Low-dose liraglutide still has high efficacy in weight reduction in Taiwanese people, especially for those of younger age.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32506681",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been shown to possess pleiotropic effects including body weight reduction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: For people with type 2 diabetes (T2DM) inadequately controlled with oral antidiabetic drugs (OADs), evidence from both randomized controlled trials (RCTs) and real-world studies has demonstrated that treatment intensification with liraglutide offers effective glycemic control, weight reduction, and a lower risk of hypoglycemia compared to treatment intensification with insulin or additional OADs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995594",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "wise regression analysis demonstrated that baseline BMI and previous insulin dose were positively associated with body weight reduction and baseline HbA1c was positively associated with reduction of HbA1c at 2\u00a0years after liraglutide introduction.CONC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25237400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " control (placebo, sitagliptin, glimepiride, dulaglutide, insulin glargine, and NPH), liraglutide in combination with metformin resulted in significant reductions in HbA1c, bodyweight, FPG, and PPG, and similar reductions in SBP, and DBP. Moreover, liraglutide comb",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27600499",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Liraglutide (LIRA) treatment is associated with the dose-dependent reduction of weight. Hig",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27073422",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Liraglutide, a glucagon-like peptide (GLP-1) receptor agonist, has showed favorable effects in the glycaemic control and weight reduction in patients with type 2 diabetes mellitus (T2DM). The me",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27600499",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202980",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Liraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436648",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS AND RELEVANCE: Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resulted in weight loss over 56 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284720",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Liraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19930006",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32233338",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039422",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In the latter case, body weight was reduced in comparison to metformin plus glimepiride.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039422",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}